KUALA LUMPUR (Sept 6): Duopharma Biotech Bhd (KL:DPHARMA) has extended its group managing director (MD) Leonard Ariff Abdul Shatar’s contract for another year until Dec 31, 2025.
According to the pharmaceutical company’s filing with Bursa Malaysia on Friday, Leonard Ariff’s contract will commence from Dec 9, 2024 until Dec 31, 2025.
Leonard Ariff has served the role since Dec 28, 2017. Prior to his appointment as group MD, he served as the chief executive officer of CCM Duopharma Biotech Bhd from 2008 to 2017.
CCM Duopharma was formerly a subsidiary of Chemical Company of Malaysia Bhd, but de-merged from the parent in December 2017.
Duopharma said it has developed a succession plan in relation to the group MD role, and is progressing under the stewardship of the company’s nomination and remuneration committee to facilitate a smooth and effective chief executive leadership transition in due course.
Duopharma is 44.11% owned by Permodalan Nasional Bhd (PNB). The Employees Provident Fund (EPF) also holds an 8.58% indirect stake in the group.
Shares in Duopharma closed unchanged at RM1.18 on Friday, giving it a market capitalisation of RM1.14 billion.